Dr Robert James
Rob has been involved in the exploitation of early stage intellectual property for 20 years since he completed his PhD in Biochemistry in 1990. Rob worked for Cancer Research Campaign Technology for seven years before moving to Prelude Ventures, one of Europe's oldest early stage venture capital investors. He was a Founding Partner of DFJ Esprit before leaving in 2010 to establish Sixth Element Capital. Rob has been involved in many early stage technologies and businesses which in aggregate have raised well over £100m in financing. Rob's notable achievements are: key team member in raising four VC funds; central role in licensing Temodal to Schering Plough prior to it becoming a billion dollar cancer drug; financing a new method to purify DNA and RNA called Charge Switch Technology, which led to the successful $65m sale of DNA Innovations to Invitrogen in 2004 and financing the global launch of T-Spot.TB a new diagnostic product for latent tuberculosis developed by Oxford Immunotec (OXFD) which led to its successful NASDAQ floatation in November 2013.
After qualifying with KPMG as a Chartered Accountant in 1987, Ian moved into the life sciences arena in the late 1990s. Since then he has served as CFO / Finance Director and as Chief Operating Officer in a number of publicly quoted and privately owned healthcare and drug development companies, including Reneuron, KS Biomedix, Microscience, Oxford Immunotec, William Ransom and York Pharma. During that time Ian has been responsible for numerous M&A and licensing transactions and has completed a dozen financing and re-financing transactions, successfully raising in excess of £100m in equity, debt and grant finance. Having spent a short period working as Finance Director in a healthcare fund management business, Ian left in 2010 to establish Sixth Element Capital. Ian was appointed a Fellow of the Institute of Chartered Accountants in England and Wales in 2011.
Stephen has over 10 years of experience in the life sciences. Stephen started his career at the Cancer Research UK Clinical Centre in Leeds and Imperial College London, during this time he published widely in leading academic journals on various aspects of cancer biology and drug discovery. Stephen then moved to Cancer Research Technology Ltd (CRT), the commercialisation and development arm of Cancer Research UK, where he was responsible for the identification, evaluation and commercialisation of early stage intellectual property. Stephen was a key team member in the establishment of a major drug discovery alliance with FORMA Therapeutics, shortlisted by the SCRIP Awards for the Best Partnership Alliance in 2014, and was latterly Head of Alliances, Business Development at CRT. Stephen was seconded to Sixth Element Capital for 2 years prior to joining as a Partner in 2015. Stephen has a first class degree in Pharmacology and a PhD in paediatric oncology.
Ralph is a specialist in drug development asset valuation with degrees in mathematics from the Swiss Federal Institute of Technology and mathematical finance from Oxford University. Ralph first worked in financial risk consulting and corporate finance in Zurich. He co-founded Avance in 2004, a corporate finance boutique specialised in valuation where he has been involved in more than 100 fund raising rounds and license deals. He is co-author of the book "Valuation in Life Sciences" and regularly publishes on valuation and industry developments.